Yourha Kim

Yourha Kim

Auto-generated profile, based on publicly available information

Yourha Kim

Department of Hospital Pathology

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
JBJa-Seong Bae
Ja-Seong Bae
SCSeung Kyu Choi
Seung Kyu Choi
SJSora Jeon
Sora Jeon
YKYourha Kim
Yourha Kim
SLSohee Lee
Sohee Lee
Chan Kwon JungChan Kwon Jung
Chan Kwon Jung
Background. Most patients with a preoperative diagnosis of thyroid follicular neoplasm (FN) undergo diagnostic surgery to determine whether the nodule is benign or malignant. Point mutations atNRAScodon 61 are the most common mutations observed in FN. However, the clinical significance ofNRASmutation remains unclear.Methods. From 2012 to 2013, 123 consecutive patients undergoing thyroidectomy for FN were evaluated prospectively. Molecular analyses forNRAScodon 61 were performed with pyrosequencing.Results. The overall malignancy rate in FN was 48.8% (60/123). Of 123 FNs, 33 (26.8%) were positive for theNRASmutation. The sensitivity, specificity, positive predictive value, and negative predictive value of aNRASmutation-positive FN specimen to predict malignancy were 37%, 83%, 67%, and 58%, respectively. Patients with aNRAS-positive FN had a higher malignancy rate in additional thyroid nodules beyond the FN than patients with a NRAS-negative FN. The overall malignancy rate of patients with a NRAS-positive FN was significantly higher than that of patients with a NRAS-negative FN (79% versus 52%;P= 0.008).Conclusions. Determining NRAS mutation status in FN helps to improve the accuracy of thyroid cancer diagnosis and to predict cancer risk in accompanying thyroid nodules.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JHJung Hur
Jung Hur
JKJiyoung Kang
Jiyoung Kang
YKYoung Kyoon Kim
Young Kyoon Kim
SLSook Young Lee
Sook Young Lee
SJSora Jeon
Sora Jeon
Chin Kook RheeChin Kook Rhee
Chin Kook Rhee
Hur J, et al. J Korean Med Sci. 2020 Apr;35(23):e188. https://doi.org/10.3346/jkms.2020.35.e188

1 March 2022 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Open access
UCUiju Cho
Uiju Cho
YKYourha Kim
Yourha Kim
SJSora Jeon
Sora Jeon
Chan Kwon JungChan Kwon Jung
Chan Kwon Jung
Loss of CD56 expression has been regarded as a diagnostic marker of papillary thyroid carcinoma (PTC). However, certain variants of PTC can aberrantly express CD56. Using a digital image analysis tool, we evaluated H-scores of CD56 immunostaining in 216 thyroid tumors. The H-score of the CD56 of all PTCs was lower than that of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (P<0.001). The H-scores of CD56 were lower in classic PTC, the infiltrative follicular variant, and the diffuse sclerosing variant than in other PTC variants (P<0.001), whereas the H-scores were higher in tall cell variant, Warthin-like variant, and cribriform-morular variant than in classic PTC (P<0.001). The optimal cutoff value of H-scores for the CD56 expression was 180 for differentiating the NIFTP from the follicular adenoma and 30 for the differential diagnosis of NIFTP and infiltrative follicular variant PTC. CD56 expression is predominantly lost in classic and infiltrative follicular variants of PTCs and more preserved in the other histologic subtypes of PTC and NIFTP. CD56 is particularly useful for differentiating PTC from follicular-pattern thyroid neoplasms, but the aberrant expression in uncommon variants of PTC could be a diagnostic pitfall.